Biogen IncNASDAQ:BIIB
- LAST PRICE168.2800
- TODAY'S CHANGE (%)-3.7500 (-2.1799%)
- Bid / Lots168.0000/ 5
- Ask / Lots168.7500/ 2
- Open / Previous Close171.3600 / 172.0300
- Day Range
- 52 Week Range
- Volume1,405,903
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 4, 2024
DJ Biogen Is Maintained at Neutral by JP Morgan, from 9:47AM ET on Monday Nov 04, 2024 by Dow Jones
9:47AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 31, 2024
DJ Roche's Antibody Against Alzheimer's Looks the Best Yet -- Barrons.com, from 5:31PM ET on Thursday Oct 31, 2024 by Dow Jones
5:31PM ET on Thursday Oct 31, 2024 by Dow JonesDJ Biogen Is Maintained at Outperform by Oppenheimer, from 2:19PM ET on Thursday Oct 31, 2024 by Dow Jones
2:19PM ET on Thursday Oct 31, 2024 by Dow JonesDJ Biogen Is Maintained at Equal-Weight by Barclays, from 2:11PM ET on Thursday Oct 31, 2024 by Dow Jones
2:11PM ET on Thursday Oct 31, 2024 by Dow JonesDJ Biogen Is Maintained at Buy by TD Cowen, from 1:07PM ET on Thursday Oct 31, 2024 by Dow Jones
1:07PM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biogen Inc | 25.1B | 15.2x | -18.14% |
ICON PLC | 17.5B | 23.6x | +4.68% |
Moderna Inc | 16.4B | -7.5x | --- |
Grifols SA | 7.5B | 38.6x | --- |
Biontech SE | 26.1B | -51.1x | --- |
IQVIA Holdings Inc | 39.4B | 28.0x | +46.62% |
Company Information
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
Contact Information
- Headquarters
- 225 Binney StreetCAMBRIDGE, MA, United States 02142
- Phone
- 781-464-2000
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Caroline Dorsa
- President, Chief Executive Officer, Director
- Christopher Viehbacher
- Chief Financial Officer, Executive Vice President
- Michael McDonnell
- Chief Human Resource Officer, Executive Vice President
- Ginger Gregory
- Executive Vice President, Chief Legal Officer
- Susan Alexander
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.1B |
|---|---|
Revenue (TTM) | $9.6B |
Shares Outstanding | 145.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.06 |
EPS | $11.07 |
Book Value | $102.14 |
P/E Ratio | 15.2x |
Price/Sales (TTM) | 2.6 |
Price/Cash Flow (TTM) | 11.1x |
Operating Margin | 22.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
